Newly diagnosed patients treated with drugs alone more likely to progress
SAN DIEGO -- Despite the success of novel targeted agents in newly diagnosed multiple myeloma, an upfront stem cell transplant remains the best treatment choice, a researcher said here.
In a large randomized clinical trial, European investigators compared two forms of intensification therapy: high-dose melphalan (HMD) plus an autologous stem cell transplant or standard-dose bortezomib-melphalan-prednisone (VMP), according to Michele Cavo, MD, PhD, of the Bologna University School of Medicine in Italy.
After a median follow-up of nearly 32 months, the median progression-free survival (PFS) had not been reached for those getting a transplant but was 42.5 months for those getting the VMP regimen, Cavo reported at the American Society of Hematology (ASH) annual meeting.
Jump HERE for more
Stuffed Italian Sausages
1 week ago